TOKYO, May 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced restructuring of operations in Japan and introduction of the early retirement incentive program.
To realize “Strategic Plan 2018” which was announced today, Astellas focus on building and optimizing its organizational capabilities and continue pursuing Operational Excellence. Accordingly, Astellas will restructure all operations, including R&D and Sales & Marketing, and its group companies in Japan.
- Discontinue all activities in Astellas Research Technologies Co., Ltd. (“ART”) and Astellas Marketing and Sales Support Co., Ltd. (“AES”) by the end of fiscal year 2018, ending March 31, 2019 (“FY2018”).
- Discontinue all operations of Astellas Learning Institute Co., Ltd. (“ALI”) except its green-supply supporting operations by the end of FY2018
- Divest Astellas Analytical Science Laboratories Co., Ltd. to Eurofins Pharma Services LUX Holding Sarl (planned closing: within FY2018)
With these restructuring efforts, Astellas is introducing an early retirement incentive program in FY2018 for employees of Astellas, AES, ART and ALI (estimated applicants to the program: 600).
